CalciMedica is trading at $1.20, up +12.68%, with biotech-sector gains a possible backdrop, though the direct cause is unconfirmed. - No verified fresh company-specific announcement was identified for October 20. CalciMedica's FDA-alignment news concerned Auxora's Phase 2b trial design and was announced earlier. - Biotech stocks broadly advanced: 103 of 110 stocks in one industry roundup closed higher, with a +4.8% median move and +3.6% for XBI.